Fusion Imaging: A Novel Staging Modality in Testis Cancer

<p>Objective: Computed tomography and chest radiographs provide the standard imaging for staging, treatment, and surveillance of testicular germ cell neoplasms. Positron emission tomography has recently been utilized for staging, but is somewhat limited in its ability to provide anatomic local...

Full description

Bibliographic Details
Main Author: Joseph R. Sterbis, Kevin R. Rice, Marcia C. Javitt, Noah S. Schenkman, Stephen A. Brassell
Format: Article
Language:English
Published: Ivyspring International Publisher 2010-01-01
Series:Journal of Cancer
Online Access:http://www.jcancer.org/v01p0223.htm
id doaj-f8b45001d2a04ef68e0145cee0c06af8
record_format Article
spelling doaj-f8b45001d2a04ef68e0145cee0c06af82020-11-24T20:59:26ZengIvyspring International PublisherJournal of Cancer1837-96642010-01-0111223229Fusion Imaging: A Novel Staging Modality in Testis CancerJoseph R. Sterbis, Kevin R. Rice, Marcia C. Javitt, Noah S. Schenkman, Stephen A. Brassell<p>Objective: Computed tomography and chest radiographs provide the standard imaging for staging, treatment, and surveillance of testicular germ cell neoplasms. Positron emission tomography has recently been utilized for staging, but is somewhat limited in its ability to provide anatomic localization. Fusion imaging combines the metabolic information provided by positron emission tomography with the anatomic precision of computed tomography. To the best of our knowledge, this represents the first study of the effectiveness using fusion imaging in evaluation of patients with testis cancer.</p><p>Methods: A prospective study of 49 patients presenting to Walter Reed Army Medical Center with testicular cancer from 2003 to 2009 was performed. Fusion imaging was compared with conventional imaging, tumor markers, pathologic results, and clinical follow-up.</p><p>Results: There were 14 true positives, 33 true negatives, 1 false positive, and 1 false negative. Sensitivity, specificity, positive predictive value, and negative predictive value were 93.3, 97.0, 93.3, and 97.0% respectively. In 11 patient scenarios, fusion imaging differed from conventional imaging. Utility was found in superior lesion detection compared to helical computed tomography due to anatomical/functional image co-registration, detection of micrometastasis in lymph nodes (pathologic nodes &#60; 1cm), surveillance for recurrence post-chemotherapy, differentiating fibrosis from active disease in nodes &#60; 2.5cm, and acting as a quality assurance measure to computed tomography alone.</p><p>Conclusions: In addition to demonstrating a sensitivity and specificity comparable or superior to conventional imaging, fusion imaging shows promise in providing additive data that may assist in clinical decision-making.</p>http://www.jcancer.org/v01p0223.htm
collection DOAJ
language English
format Article
sources DOAJ
author Joseph R. Sterbis, Kevin R. Rice, Marcia C. Javitt, Noah S. Schenkman, Stephen A. Brassell
spellingShingle Joseph R. Sterbis, Kevin R. Rice, Marcia C. Javitt, Noah S. Schenkman, Stephen A. Brassell
Fusion Imaging: A Novel Staging Modality in Testis Cancer
Journal of Cancer
author_facet Joseph R. Sterbis, Kevin R. Rice, Marcia C. Javitt, Noah S. Schenkman, Stephen A. Brassell
author_sort Joseph R. Sterbis, Kevin R. Rice, Marcia C. Javitt, Noah S. Schenkman, Stephen A. Brassell
title Fusion Imaging: A Novel Staging Modality in Testis Cancer
title_short Fusion Imaging: A Novel Staging Modality in Testis Cancer
title_full Fusion Imaging: A Novel Staging Modality in Testis Cancer
title_fullStr Fusion Imaging: A Novel Staging Modality in Testis Cancer
title_full_unstemmed Fusion Imaging: A Novel Staging Modality in Testis Cancer
title_sort fusion imaging: a novel staging modality in testis cancer
publisher Ivyspring International Publisher
series Journal of Cancer
issn 1837-9664
publishDate 2010-01-01
description <p>Objective: Computed tomography and chest radiographs provide the standard imaging for staging, treatment, and surveillance of testicular germ cell neoplasms. Positron emission tomography has recently been utilized for staging, but is somewhat limited in its ability to provide anatomic localization. Fusion imaging combines the metabolic information provided by positron emission tomography with the anatomic precision of computed tomography. To the best of our knowledge, this represents the first study of the effectiveness using fusion imaging in evaluation of patients with testis cancer.</p><p>Methods: A prospective study of 49 patients presenting to Walter Reed Army Medical Center with testicular cancer from 2003 to 2009 was performed. Fusion imaging was compared with conventional imaging, tumor markers, pathologic results, and clinical follow-up.</p><p>Results: There were 14 true positives, 33 true negatives, 1 false positive, and 1 false negative. Sensitivity, specificity, positive predictive value, and negative predictive value were 93.3, 97.0, 93.3, and 97.0% respectively. In 11 patient scenarios, fusion imaging differed from conventional imaging. Utility was found in superior lesion detection compared to helical computed tomography due to anatomical/functional image co-registration, detection of micrometastasis in lymph nodes (pathologic nodes &#60; 1cm), surveillance for recurrence post-chemotherapy, differentiating fibrosis from active disease in nodes &#60; 2.5cm, and acting as a quality assurance measure to computed tomography alone.</p><p>Conclusions: In addition to demonstrating a sensitivity and specificity comparable or superior to conventional imaging, fusion imaging shows promise in providing additive data that may assist in clinical decision-making.</p>
url http://www.jcancer.org/v01p0223.htm
work_keys_str_mv AT josephrsterbiskevinrricemarciacjavittnoahsschenkmanstephenabrassell fusionimaginganovelstagingmodalityintestiscancer
_version_ 1716782405898993664